Ribosomal Proteins RPS11 and RPS20, Two Stress-Response Markers of Glioblastoma Stem Cells, Are Novel Predictors of Poor Prognosis in Glioblastoma Patients

Glioblastoma stem cells (GSC) co-exhibiting a tumor-initiating capacity and a radio-chemoresistant phenotype, are a compelling cell model for explaining tumor recurrence. We have previously characterized patient-derived, treatment-resistant GSC clones (TRGC) that survived radiochemotherapy. Compared to glucose-dependent, treatment-sensitive GSC clones (TSGC), TRGC exhibited reduced glucose dependence that favor the fatty acid oxidation pathway as their energy source. Using comparative genome-wide transcriptome analysis, a series of defense signatures associated with TRGC survival were identified and verified by siRNA-based gene knockdown experiments that led to loss of cell integrity. In this study, we investigate the prognostic value of defense signatures in glioblastoma (GBM) patients using gene expression analysis with Probeset Analyzer (131 GBM) and The Cancer Genome Atlas (TCGA) data, and protein expression with a tissue microarray (50 GBM), yielding the first TRGC-derived prognostic biomarkers for GBM patients. Ribosomal protein S11 (RPS11), RPS20, individually and together, consistently predicted poor survival of newly diagnosed primary GBM tumors when overexpressed at the RNA or protein level [RPS11: Hazard Ratio (HR) = 11.5, p<0.001; RPS20: HR = 4.5, p = 0.03; RPS11+RPS20: HR = 17.99, p = 0.001]. The prognostic significance of RPS11 and RPS20 was further supported by whole tissue section RPS11 immunostaining (27 GBM; HR = 4.05, p = 0.01) and TCGA gene expression data (578 primary GBM; RPS11: HR = 1.19, p = 0.06; RPS20: HR = 1.25, p = 0.02; RPS11+RPS20: HR = 1.43, p = 0.01). Moreover, tumors that exhibited unmethylated O-6-methylguanine-DNA methyltransferase (MGMT) or wild-type isocitrate dehydrogenase 1 (IDH1) were associated with higher RPS11 expression levels [corr (IDH1, RPS11) = 0.64, p = 0.03); [corr (MGMT, RPS11) = 0.52, p = 0.04]. These data indicate that increased expression of RPS11 and RPS20 predicts shorter patient survival. The study also suggests that TRGC are clinically relevant cells that represent resistant tumorigenic clones from patient tumors and that their properties, at least in part, are reflected in poor-prognosis GBM. The screening of TRGC signatures may represent a novel alternative strategy for identifying new prognostic biomarkers.

[1]  Bin Huang,et al.  Clinicopathological and Prognostic Significance of CD133 in Glioma Patients: A Meta-Analysis , 2015, Molecular Neurobiology.

[2]  K. Tsubota,et al.  Oxidative Stress Induced Age Dependent Meibomian Gland Dysfunction in Cu, Zn-Superoxide Dismutase-1 (Sod1) Knockout Mice , 2014, PloS one.

[3]  R. Coleman,et al.  Ribosomal protein–Mdm2–p53 pathway coordinates nutrient stress with lipid metabolism by regulating MCD and promoting fatty acid oxidation , 2014, Proceedings of the National Academy of Sciences.

[4]  K. Hoang-Xuan,et al.  Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. , 2014, The New England journal of medicine.

[5]  K. Aldape,et al.  A randomized trial of bevacizumab for newly diagnosed glioblastoma. , 2014, The New England journal of medicine.

[6]  S. Nelson,et al.  Protective Properties of Radio-Chemoresistant Glioblastoma Stem Cell Clones Are Associated with Metabolic Adaptation to Reduced Glucose Dependence , 2013, PloS one.

[7]  C. Ishioka,et al.  The expression status of CD133 is associated with the pattern and timing of primary glioblastoma recurrence. , 2013, Neuro-oncology.

[8]  X. Jacq,et al.  Ribosomal Proteins RPL37, RPS15 and RPS20 Regulate the Mdm2-p53-MdmX Network , 2013, PloS one.

[9]  P. Lichter,et al.  LGR5 is a Marker of Poor Prognosis in Glioblastoma and is Required for Survival of Brain Cancer Stem‐Like Cells , 2013, Brain pathology.

[10]  Michael Weller,et al.  Standards of care for treatment of recurrent glioblastoma--are we there yet? , 2013, Neuro-oncology.

[11]  M. Lindström,et al.  p53 -Dependent and -Independent Nucleolar Stress Responses , 2012, Cells.

[12]  K. Tsubota,et al.  Age-related dysfunction of the lacrimal gland and oxidative stress: evidence from the Cu,Zn-superoxide dismutase-1 (Sod1) knockout mice. , 2012, The American journal of pathology.

[13]  Jeong-Hyeon Kim,et al.  Calorie restriction (CR) reduces age-dependent decline of non-homologous end joining (NHEJ) activity in rat tissues , 2011, Experimental Gerontology.

[14]  F. Shang,et al.  Ubiquitin-proteasome pathway and cellular responses to oxidative stress. , 2011, Free radical biology & medicine.

[15]  Yanping Zhang,et al.  The Ribosomal Protein-Mdm2-p53 Pathway and Energy Metabolism: Bridging the Gap between Feast and Famine. , 2011, Genes & cancer.

[16]  Paul S Mischel,et al.  Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  M. Blasco,et al.  SIRT1 contributes to telomere maintenance and augments global homologous recombination , 2010, The Journal of cell biology.

[18]  G. Reifenberger,et al.  Patients with IDH 1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH 1-mutated glioblastomas , and IDH 1 mutation status accounts for the unfavorable prognostic effect of higher age : implications for classification of gliomas , 2010 .

[19]  C. Deisenroth,et al.  Ribosome biogenesis surveillance: probing the ribosomal protein-Mdm2-p53 pathway , 2010, Oncogene.

[20]  Linda Partridge,et al.  Extending Healthy Life Span—From Yeast to Humans , 2010, Science.

[21]  G. Reifenberger,et al.  Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  P. Kleihues,et al.  IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas , 2009, Clinical Cancer Research.

[23]  K. Hoang-Xuan,et al.  Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  T. Mikkelsen,et al.  The induction of autophagy by γ‐radiation contributes to the radioresistance of glioma stem cells , 2009, International journal of cancer.

[25]  Sterling C. Johnson,et al.  Caloric Restriction Delays Disease Onset and Mortality in Rhesus Monkeys , 2009, Science.

[26]  S. Nelson,et al.  Molecular properties of CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumors , 2009, Journal of Neuro-Oncology.

[27]  R. Mirimanoff,et al.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.

[28]  S. Horvath,et al.  Neurosphere Formation Is an Independent Predictor of Clinical Outcome in Malignant Glioma , 2009, Stem cells.

[29]  R. Béliveau,et al.  Modulation of invasive properties of CD133(+) glioblastoma stem cells: A role for MT1‐MMP in bioactive lysophospholipid signaling , 2009, Molecular carcinogenesis.

[30]  J. Herman,et al.  Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  E. Domany,et al.  Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  Jack Cuzick,et al.  Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  P. Lichter,et al.  Stem Cell Marker CD133 Affects Clinical Outcome in Glioma Patients , 2008, Clinical Cancer Research.

[34]  R. Arceci.  Glioma stem cells promote radioresistance by preferential activation of the DNA damage response , 2008 .

[35]  E. Bergamini,et al.  The Role of Autophagy in Aging , 2007, Annals of the New York Academy of Sciences.

[36]  F. Muller,et al.  Trends in oxidative aging theories. , 2007, Free radical biology & medicine.

[37]  Tetsurou Yamamoto.  Roles of the ribosomal protein S19 dimer and the C5a receptor in pathophysiological functions of phagocytic leukocytes , 2007, Pathology international.

[38]  G. Broggi,et al.  Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells , 2006, Nature.

[39]  Mark W. Dewhirst,et al.  Glioma stem cells promote radioresistance by preferential activation of the DNA damage response , 2006, Nature.

[40]  S. Pomeroy,et al.  Medulloblastoma outcome is adversely associated with overexpression of EEF1D, RPL30, and RPS20 on the long arm of chromosome 8 , 2006, BMC Cancer.

[41]  M. Toyota,et al.  Activation of the ribosomal protein L13 gene in human gastrointestinal cancer. , 2006, International journal of molecular medicine.

[42]  L. Ricci-Vitiani,et al.  Chemotherapy resistance of glioblastoma stem cells , 2006, Cell Death and Differentiation.

[43]  C. Foster,et al.  Ribosomal Protein L19 Is a Prognostic Marker for Human Prostate Cancer , 2006, Clinical Cancer Research.

[44]  Koji Yoshimoto,et al.  Distinct transcription profiles of primary and secondary glioblastoma subgroups. , 2006, Cancer research.

[45]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[46]  Wilhelm Haas,et al.  Nutrient control of glucose homeostasis through a complex of PGC-1α and SIRT1 , 2005, Nature.

[47]  Steven P Gygi,et al.  Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. , 2005, Nature.

[48]  D. Farkas,et al.  Isolation of cancer stem cells from adult glioblastoma multiforme , 2004, Oncogene.

[49]  R. Henkelman,et al.  Identification of human brain tumour initiating cells , 2004, Nature.

[50]  Ugo Orfanelli,et al.  Isolation and Characterization of Tumorigenic, Stem-like Neural Precursors from Human Glioblastoma , 2004, Cancer Research.

[51]  Myriam Gorospe,et al.  Calorie Restriction Promotes Mammalian Cell Survival by Inducing the SIRT1 Deacetylase , 2004, Science.

[52]  Zhijian J. Chen,et al.  Erratum: The novel functions of ubiquitination in signaling (Current Opinion in Cell Biology (2004) 16 (119) PII: S0955067404000146) , 2004 .

[53]  Zhijian J. Chen,et al.  The novel functions of ubiquitination in signaling. , 2004, Current opinion in cell biology.

[54]  Daniel H. Geschwind,et al.  Cancerous stem cells can arise from pediatric brain tumors , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[55]  Taka-Aki Sato,et al.  Differential Expression of Ribosomal Proteins in Human Normal and Neoplastic Colorectum , 2003, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[56]  D. C. Cabelof,et al.  Caloric restriction promotes genomic stability by induction of base excision repair and reversal of its age-related decline. , 2003, DNA repair.

[57]  S. Irie,et al.  Electrophoretic characterization of ribosomal subunits and proteins in apoptosis: specific downregulation of S11 in staurosporine-treated human breast carcinoma cells. , 2001, Biochemistry.

[58]  Xiu-qin Wang,et al.  Cloning and characterization of full-length human ribosomal protein L15 cDNA which was overexpressed in esophageal cancer. , 2001, Gene.

[59]  H. Naora,et al.  Involvement of ribosomal proteins in regulating cell growth and apoptosis: Translational modulation or recruitment for extraribosomal activity? , 1999, Immunology and cell biology.

[60]  D. Bigner,et al.  Molecular pathogenesis of malignant gliomas. , 1999, Current opinion in oncology.

[61]  Y. Ioannou,et al.  Ribosomal proteins in cell proliferation and apoptosis. , 1999, International reviews of immunology.

[62]  M. Vaarala,et al.  Several genes encoding ribosomal proteins are over‐expressed in prostate‐cancer cell lines: Confirmation of L7a and L37 over‐expression in prostate‐cancer tissue samples , 1998, International journal of cancer.

[63]  P. Lam,et al.  The molecular genetics of central nervous system tumors , 1998, Pathology.

[64]  I. Wool.  Extraribosomal functions of ribosomal proteins. , 1996, Trends in biochemical sciences.

[65]  I. Wool,et al.  Ribosomal protein genes are overexpressed in colorectal cancer: isolation of a cDNA clone encoding the human S3 ribosomal protein , 1991, Molecular and cellular biology.

[66]  S. Ferrari,et al.  Noncoordinated expression of S6, S11, and S14 ribosomal protein genes in leukemic blast cells. , 1990, Cancer research.

[67]  A. Fornace,et al.  Ubiquitin mRNA is a major stress-induced transcript in mammalian cells. , 1989, Nucleic acids research.

[68]  D. Mutch,et al.  Endometrial adenocarcinoma estrogen receptor content: association of clinicopathologic features with immunohistochemical analysis compared with standard biochemical methods. , 1987, American journal of obstetrics and gynecology.

[69]  D. Mutch,et al.  Immunohistochemical analyses of estrogen receptor in endometrial adenocarcinoma using a monoclonal antibody. , 1986, Cancer research.